Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients

Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients

BackgroundRechallenge with EGFR inhibitors represents a promising strategy for patients with RAS wild type (WT) colorectal cancer (CRC) but definitive selection criteria are lacking. Recently, the RAS WT status on circulating tumor DNA (ct-DNA) emerged as a potential watershed for this strategy. Our...

Full description

Bibliographic Details
Main Authors: Stefano Mariani, Marco Puzzoni, Riccardo Giampieri, Pina Ziranu, Valeria Pusceddu, Clelia Donisi, Mara Persano, Giovanna Pinna, Erika Cimbro, Alissa Parrino, Dario Spanu, Andrea Pretta, Eleonora Lai, Nicole Liscia, Alessio Lupi, Enrica Giglio, Grazia Palomba, Milena Casula, Marina Pisano, Giuseppe Palmieri, Mario Scartozzi
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-04-01
Series:Frontiers in Oncology
Subjects:
colorectal (colon) cancer
epidermal growth factor receptor (EGFR)
RAS
liquid biopsy
rechallenge
cetuximab
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.852583/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.852583/full

Similar Items